课题基金 / 基金详情

PHARMACOKINETICS & TOLERANCE OF GANCICLOVIR IN HIV INFECTED CHILDREN

PHARMACOKINETICS & TOLERANCE OF GANCICLOVIR IN HIV INFECTED CHILDREN
药代动力学
批准号：
5217731
负责人：
JOSEPH CHURCH
金额：
$0.0万
依托单位：
--
依托单位国家：
美国
项目类别：
财政年份：
--
资助国家：
美国
项目状态：
未结题
起止时间：
至
来源：
https://reporter.nih.gov/project-details/5217731
关键词：
AIDS therapy HIV infections adolescence (12-20) child (0-11) clinical research clinical trials cytomegalovirus drug administration rate /duration drug adverse effect drug screening /evaluation drug tolerance ganciclovir human immunodeficiency virus human subject human therapy evaluation opportunistic infections oral administration pediatric AIDS pediatric pharmacology pharmacokinetics

项目摘要

项目成果

JOSEPH CHURCH的其他基金

相似基金

相关文献

中文摘要
翻译
年龄在两周到二十岁之间、携带艾滋病毒和 将巨细胞病毒纳入本研究，以评估其安全性和 新药更昔洛韦的副作用。这样做的目的是 一项研究旨在确定口服更昔洛韦是否可以耐受 当给感染艾滋病毒的婴儿和感染CMV的儿童服用24周时 感染，并确定最大耐受量和副作用 口服更昔洛韦的疗效。
英文摘要
Individuals between two weeks to twenty years of age who have an HIV and cytomegalovirus are enrolled in this study to evaluate the safety and side effects of a new oral medication, ganciclovir. The purpose of this study is to determine if an oral form of ganciclovir can be tolerated when given for 24 weeks to HIV infected infants and children with CMV infection and to determine what is the maximum tolerable dose and side effects of oral ganciclovir.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
IN VIVO ASSESSMENT OF CLINICALLY RELEVANT AUTOANTIBODIES IN IVIG PREPARATIONS
SAFETY AND IMMUNOGENICITY OF OKA/MERCK VARICELLA VIRUS VACCINE IN CHILDREN W/HIV
SAFETY AND IMMUNOGENICITY OF OKA/MERCK VARICELLA VIRUS VACCINE IN CHILDREN W/HIV
SAFETY AND IMMUNOGENICITY OF OKA/MERCK VARICELLA VACCINE
海外基金